Clinical Research

Repository: All Types of Amyloidosis
H-22838: Data, Tissue, Blood, And Urine Repository For Amyloid Diseases 2000-455G
H-33317: Serum Biomarker Identification of Cardiac Amyloidosis in Elderly African Americans
AL Amyloidosis
IRB #2012-1122/Millennium C16011:  A Phase 3, Randomized, Controlled, Open-label, Multicenter,Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
H-35360 (Janssen #54767414AMY2002): A Phase I-II Trial of Daratumumab for the treatment of patients with AL amyloidosis
ATTRwt (Wild Type) Amyloidosis
H-28609: A Study of Serum Transthyretin Aggregates And Association With Disease Progression In Patients With Senile Systemic Amyloidosis
ATTRmt (Mutant TTR, Familial) Amyloidosis
ISIS 420915-CS3:  IONIS OPEN LABEL EXTENSION STUDY: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP)
B3461045TAFAMIDIS OPEN LABEL EXTENSION STUDY: A Multicenter, International, Phase 3, Double-Blind, Randomized, Extension Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
ALN-TTR02-006: PATISIRAN OPEN LABEL EXTENSION STUDY: A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study
ALN-TTR02-007: PATISIRAN EXPANDED ACCESS PROGRAM: Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy